Product Description: Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]McGavin JK, et al. Gemtuzumab ozogamicin. Drugs. 2001;61(9):1317-22; discussion 1323-4. /[2]Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia. National Cancer Institute. 2017 Sept.
Molecular Weight: N/A
Compound Purity: 96.10
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody
English
Deutsch
